Table 2.
HE4 and CA 125 serum levels in patients with ovarian cancer, subdivided according to tumour stage and histological type
| Patients (n) | HE4 >150 pmol/L | Median±SE pmol/L | Range pmol/L | 95 percentile pmol/L | CA 125 >35 U/mL | Median±SE U/mL | Range (U/ml) | 95 percentile U/ml | One or another+ | ROMA | ROMA+ (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stages I–II | 19 | 14 (73.7%) | 221.5 ± 56 | 47.9–954.1 | 954.1 | 11 (57.9%) | 39.2 ± 33.8 | 7–514 | 514 | 15 (78.9%) | 77.3 + 8.1 | 14 (73.7) |
| Stage III | 48 | 36 (75%) | 415.3 ± 88.4 | 17.2–2787 | 2,067.9 | 42 (87.5%) | 162 ± 206.6 | 2–8,630 | 3,434.3 | 47 (97.9%) | 85.4 + 3.7 | 45 (93.8) |
| Stage IV | 44 | 38 (86.4%) | 524.8 ± 170.5 | 25–7341 | 2,122 | 39 (88.6%) | 396 ± 189.4 | 11–7,351 | 3,003.8 | 43 (97.7%) | 89.3 + 3.9 | 41 (93.2) |
| Serous papilar | 84 | 72 (85.7%) | 512.5 ± 100.2 | 17.2–7341 | 2,122 | 72 (85.7%) | 235 ± 151.4 | 2–8,630 | 3,239 | 83 (98.8%) | 89.3 + 2.5 | 81 (96.4) |
| Mucinous | 13 | 7 (53.9%) | 189.5 ± 52.6 | 25–636.4 | 636.4 | 8 (61.6%) | 54 ± 44.6 | 8–514 | 514 | 9 (69.2%) | 34 + 10.5 | 7 (53.8) |
| Other histologies | 14 | 9 (64.3%) | 267.5 ± 124.2 | 43.2–1651 | 1,651 | 12 (85.7%) | 158 ± 172.3 | 12−2,210 | 2,210 | 13 (92.9%) | 85.2 + 8.5 | 12 (85.7) |
ROMA Risk of Ovarian Malignancy Algorithm